Finanzen von RenovoRx Inc (RNXT)RNXTRenovoRx Inc

Evaluating the bottom line, RenovoRx Inc maintains a gross margin of 84.27%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -368.43%, while the net margin is -320.24%. These profitability ratios, combined with a Return on Equity (ROE) of -125.23%, provide a clear picture of how effectively RNXT converts its operational activities into shareholder value.

In the context of the broader market, RNXT competes directly with industry leaders such as FRMM and CING. With a market capitalization of $75.37M, it holds a significant position in the sector. When comparing efficiency, RNXT's gross margin of 84.27% stands against FRMM's 29.16% and CING's N/A. Such benchmarking helps identify whether RenovoRx Inc is trading at a premium or discount relative to its financial performance.

RenovoRx reported a record revenue of $909,000 for Q2 2026, a 61% sequential increase and a 115% year-over-year rise. The gross margin for Q2 2026 was 84%, indicating strong operational efficiency.